A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects with Type 2 Diabetes

Trial Identifier: D5670C00004
Sponsor: AstraZeneca
Collaborator:
MedImmune, LLC
NCTID:: NCT03235050
Start Date: August 2017
Primary Completion Date: May 2018
Study Completion Date: June 2019
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations